Monday, 12 May 2014
www.regonline.co.uk/cancerscreen2014
Cineworld: The O2, London, SE10 0DX, UK
This event will discuss current research and clinical trials for the prevention of cancer, focussing on screening, early detection and chemoprevention. The meetings will be run in an informal setting with plenty of opportunity for networking and debate.
This event has CPD accreditation and is part of the
Controlling Cancer Summit 2014 -www.controllingcancersummit2014.com
The Deadline for abstract submissions for oral presentation is Feb 10th 2014
Abstracts for poster presentation only can be submitted up to two weeks before the event
.
You can download the instructions for authors at
www.euroscicon.com/AbstractsForOralAndPosterPresentation.pdf
Talk times include 5 – 10 minutes for questions
9:00 – 9:45 Registration
9:45 – 10:00 Introduction by the Chair:
10:00 – 10:30 Talk to be confirmed
10:30 – 11:00 Head and Neck Cancer (HNC) Screening in National and High-risk Populations in Ireland
Dr Eleanor O’Sullivan, Clinical Lecturer, Cork University Dental School & Hospital, Ireland
Despite increasingly aggressive therapies, HNC 5-year survival rates (<50%) have remained relatively unchanged for 40yrs due largely to continued late presentation. This paper presents the Irish experience of targeted screening among high-risk individuals and subsequent development of a National HNC Awareness campaign. This campaign, now in its 4th year, aimed to increase public awareness, highlight modifiable risk factors, and stress potential role of dental professionals in early detection. National Mouth Cancer Awareness Day (MCAD) was established and the public encouraged to attend for free mouth cancer examinations/advice. The presentation shares lessons learned in the development and implementation of this intervention.
11:00 – 11:30 Speakers’ photo then mid-morning break and poster exhibition and trade show
Please try to visit all the exhibition stands during your day at this event. Not only do our sponsors enable Euroscicon to keep the registration fees competitive, but they are also here specifically to talk to you
11:30 – 12:00 Quality Control in Cervical Cancer Screening
Dr Alenka Repše Fokter, MD, Ph.D, MIAC, cytopathologist, Dept. of Pathology and Cytology, Celje general Hospital, Slovenia
In order to be successful cervical cancer screening programmes should be organised. European guidelines strongly advise that the standards for quality assurance and quality control should be implemented in each cytology laboratory and short- and long-term results of the screening programme should be regularly monitored. Additionally, communication between cytologists, pathologists, gynaecologists and all others who are involved in the screening programme is very important. Gynaecologists should be informed about their percentage of pathological and unsatisfactory smears in comparison with the country and laboratory average. It is recommended to hold periodical interdisciplinary meetings where all the complicated cases can be discussed.
12:00 – 12:30 ORAL PRESENTATIONS
12:30 – 13:30 Lunch, poster exhibition and trade show
Please try to visit all the exhibition stands during your day at this event. Not only do our sponsors enable Euroscicon to keep the registration fees competitive, but they are also here specifically to talk to you
13:30 – 14:30 Discussion Panel
14: 30 – 15:00 The European Prostate cancer screening trial ERSPC: outcomes and methods for risk stratification.
Dr Monique Roobol, Associate professor, epidemiologist, Erasmus University Medical center, Rotterdam, The Netherlands
Systematic PSA based prostate cancer screening has proven to be able to reduce prostate cancer morbidity and mortality with app. 40% and 30% res. Unfortunaltely the screening tests used lack sensitivity and specificity to identify only those prostate cancers that are life threathening. Hence, PSA based screening also results in over diagnosis and subsequent over treatment of indolent prostate cancer that without screening would never have lead to compliants or death. A better riskstratification is therefor warranted.
15:00 – 15:30 Afternoon Tea, last poster session and trade show
15:30 – 16:00 Estonian experience in establishing a cancer screening registry: opportunities and challenges of the e-health era
Dr Piret Veerus, Senior researcher, National Institute for Health Development, Estonia
Experiences in establishing a central electronic cancer screening registry in Estonia which is purely based on acquiring data from patients’ electronic health records at the outpatient clinics and hospitals.
16:00 – 16:30 Mammography Screening for Breast Cancer. Is it living up to its promise?
Dr Anthony Miller, Professor Emeritus, Dalla Lana School of Public Health, University of Toronto, Canada
Mammography screening was introduced following randomised screening trials conducted before recent advances in breast cancer treatment. One exception, the Canadian trial, found no benefit of mammography, even after long-term follow-up. Women were disadvantaged because of the costs of diagnostic interventions, and over-diagnosis of breast cancer. Over-diagnosis is now recognised as a major adverse consequence of many screening tests. Studies in populations utilising mammography screening that take note of advances in breast cancer treatment have found little impact upon breast cancer mortality. It is necessary to reassess the costs and benefits of mammography screening and consider other breast cancer control measures.
16:30 - 17:00 Chairman’s summing up
About the Speakers
Anthony Miller, a physician-epidemiologist, was a scientific staff member, UK Medical Research Council, 1962-71, Director, Epidemiology Unit, National Cancer Institute of Canada, 1971-86, Chair, Department of Preventive Medicine and Biostatistics, University of Toronto, 1992-6, special expert, Division of Cancer Prevention, US National Cancer Institute, 1997, Senior Epidemiologist, International Agency for Research on Cancer, 1998-9, Head, Division of Cancer Epidemiology, German Cancer Research Centre, Heidelberg, 2000-3 and Associate Director, Research, Dalla Lana School of Public Health, University of Toronto, 2008-10. He is Scientific Lead of the Cancer Risk Management Initiative of the Canadian Partnership against Cancer.
Alenka Repše Fokter is Assistant Professor at Medical Faculty, University of Maribor, Slovenia and head of Cytopathology laboratory in Celje General Hospital. She is actively included in the national cervical cancer screening programme and is a member of the Slovenian advisory board of the national cervical cancer screening programme. She is a member of the Medical Chamber of Slovenia, Slovene Medical Association, Slovenian Society of Pathology, Slovenian Society of Cytopathology, European Society of Pathology, International Academy of Cytology, president of Expanded expert committee of Pathology and Forensic Medicine of the Ministry of Health and national editor of Acta Cytologica.
Monique J. Roobol is associate professor and the head of the screening office of the Department of Urology at Erasmus Medical Centre Rotterdam, The Netherlands. She has a master and PhD degree in epidemiology. In the past she worked as a research technician in molecular biology. She is responsible for the Dutch part of the European Randomized study of Screening for prostate cancer (www.erspc.org) and the worldwide prostate cancer active surveillance project PRIAS ( www.prias-project.org). She has (co)-authored app 200 scientific papers and book chapters.
Piret Veerus has been involved in cancer screening research since 2004. Member of the European Network for Indicators on Cancer (EUNICE) 2005-2007; member of Eurochip-2 Task Force of Cervical Screening 2003-2007; member of Eurochip-3 WP4 on Cervical Cancer Screening 2008-2012. Member of expert panel of cancer screening in Estonia. Member of expert panel of cervical pathology diagnosis and surveillance guidelines in Estonia. Several international publications on cancer screening in Europe.
As Clinical Lecturer in Oral/Maxillofacial Surgery and Member of Regional HNC MDT, Eleanor O’Sullivan is involved in clinical care of HNC patients from diagnosis to palliation. Research interests include primary prevention, early detection and optimizing HNC patient’s journey. As a member of ICS HNC Expert Advisory Panel and Chair of MHNCAI, she played a lead role in developing and implementing National Mouth Cancer Awareness Days (MCAD) 2010-2013. MHNCAI has established links with HNC awareness groups in UK, Scotland, USA and Sudan. She has conducted several HNC screening studies and collaborates with National Cancer Registry, Dublin City University and Khartoum University, Sudan
Post expires at 12:15pm on Monday May 12th, 2014
Tags: breast cancer, Cancer, cancer awareness, cancer screening registry, cervical cancer screening, chemoprevention, e-health, early detection, epigenetic, mammography, MCAD campaign, Mouth Head and Neck Cancer, oncology, over-diagnosis, overdiagnosis, Pap smear, personalised medicine, prostate cancer, quality control, risk stratification, screen, screening., targeted screening, treatment
Follow Us!